HC Wainwright & Co. Initiates Coverage On Kyverna Therapeutics with Neutral Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral rating and set a price target of $8.
July 03, 2024 | 10:20 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has initiated coverage on Kyverna Therapeutics with a Neutral rating and set a price target of $8.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. The price target of $8 provides a benchmark for investors but does not indicate a strong buy or sell signal.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100